Literature DB >> 6295003

The clinical illness promotion factor: a third ingredient.

A S Evans.   

Abstract

The interactions between a causative agent and a susceptible host involve a series of responses most of which are subclinical or asymptomatic but a few of which are manifested by clinical illness. The factor(s) which tip the balance are poorly understood in both acute and chronic diseases. It is designated here as the clinical illness promoting factor (CIPF), a third ingredient. Among infected persons some leads have been found as to why clinical illness develops: in tuberculosis genetic susceptibility plays a key role, as shown in twin studies; in EBV infections age at the time of infection, genetic, and psychosocial factors determine both the expression and the severity of illness; in poliomyelitis age, exercise in the incubation period, and genetic background are related to the development of paralysis. In the relationship between viruses and cancer, viruses and chronic diseases, or inanimate pathogens like tobacco and lung cancer, we know very little as to the factors that result in clinical disease among the many who are presumably susceptible and fully exposed. Epidemiologic study is urged to identify this CIPF or "third ingredient."

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6295003      PMCID: PMC2596440     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  11 in total

1.  Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study.

Authors:  G de-Thé; A Geser; N E Day; P M Tukei; E H Williams; D P Beri; P G Smith; A G Dean; G W Bronkamm; P Feorino; W Henle
Journal:  Nature       Date:  1978-08-24       Impact factor: 49.962

2.  Psychosocial risk factors in the developmental of infectious mononucleosis.

Authors:  S V Kasl; A S Evans; J C Niederman
Journal:  Psychosom Med       Date:  1979-10       Impact factor: 4.312

3.  Epidemiology of hodgkin's disease in the young.

Authors:  N Gutensohn; P Cole
Journal:  Int J Cancer       Date:  1977-05-15       Impact factor: 7.396

4.  Serum IgA antibodies to Epstein-Barr virus capsid antigen preceding symptoms of nasopharyngeal carcinoma.

Authors:  H C Ho; H C Kwan; M H Ng; G de The
Journal:  Lancet       Date:  1978-02-25       Impact factor: 79.321

5.  Presence of elevated antibody titres to Epstein-Barr virus before Hodgkin's disease.

Authors:  A S Evans; G W Comstock
Journal:  Lancet       Date:  1981-05-30       Impact factor: 79.321

6.  Epstein-Barr virus-specific antibody titers in seven Alaskan natives before and after diagnosis of nasopharyngeal carcinoma.

Authors:  A P Lanier; W Henle; T R Bender; G Henle; M L Talbot
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

7.  Variable phenotypic expression of an X-linked recessive lymphoproliferative syndrome.

Authors:  D T Purtilo; D DeFlorio; L M Hutt; J Bhawan; J P Yang; R Otto; W Edwards
Journal:  N Engl J Med       Date:  1977-11-17       Impact factor: 91.245

8.  Application of an immunoenzymatic method and an immunoautoradiographic method for a mass survey of nasopharyngeal carcinoma.

Authors:  Z Yi; L Yuxi; L Chunren; C Sanwen; W Jihneng; Z Jisong; Z Huijong
Journal:  Intervirology       Date:  1980       Impact factor: 1.763

9.  Causation and disease: the Henle-Koch postulates revisited.

Authors:  A S Evans
Journal:  Yale J Biol Med       Date:  1976-05

10.  Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years.

Authors:  T J Hallee; A S Evans; J C Niederman; C M Brooks; j H Voegtly
Journal:  Yale J Biol Med       Date:  1974-09
View more
  3 in total

Review 1.  Mixed viral infections: detection and management.

Authors:  J L Waner
Journal:  Clin Microbiol Rev       Date:  1994-04       Impact factor: 26.132

Review 2.  Role of viral infections in the induction of adverse drug reactions.

Authors:  M Levy
Journal:  Drug Saf       Date:  1997-01       Impact factor: 5.228

3.  Co-carcinogenesis: Human Papillomaviruses, Coal Tar Derivatives, and Squamous Cell Cervical Cancer.

Authors:  Harry W Haverkos; Gregory P Haverkos; Michael O'Mara
Journal:  Front Microbiol       Date:  2017-11-16       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.